The American Journal of Medicine
Volume 123, Issue 3 , Pages 198-204, March 2010

Atrial Fibrillation in Heart Failure: A Comprehensive Review

  • Prakash C. Deedwania, MD

      Affiliations

    • Department of Medicine, University of California, San Francisco School of Medicine, San Francisco, Calif
    • Department of Cardiology, Veterans Affairs Medical Center, Fresno, Calif
    • Corresponding Author InformationRequests for reprints should be addressed to Prakash C. Deedwania, MD, Division of Cardiology, VA Medical Center, 2615 E Clinton Avenue, Fresno, CA 93703
    • ,
  • Joel A. Lardizabal, MD

      Affiliations

    • Division of Cardiology, University of California, San Francisco School of Medicine, Fresno Medical Education Program, Fresno

Abstract 

Chronic heart failure and atrial fibrillation are 2 major disorders that are closely linked. Their coexistence is associated with adverse prognosis. Both share several common predisposing conditions, but their interaction involves complex ultrastructural, electrophysiologic, and neurohormonal processes that go beyond mere sharing of mutual risk factors. Rate control approach remains the standard therapy for atrial fibrillation in heart failure because current strategies at rhythm control have so far failed to positively impact mortality and morbidity. This is largely because of the shortcomings of current pharmacologic anti-arrhythmic agents. Surgical and catheter-based therapies are promising, but long-term data are lacking. The role of non-anti-arrhythmic therapeutic agents also is being explored. Further progress toward improved understanding the complex relationship between atrial fibrillation and heart failure should improve management strategies.

Keywords: Arrhythmia, Atrial fibrillation, Cardiomyopathy, Heart failure

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Funding: None.

 Conflict of Interest: Dr Lardizabal does not have any relationship with industry and financial associations that might pose a conflict of interest. Dr Deedwania was a consultant and speaker and has been on the Advisory Board of Sanofi-Aventis.

 Authorship: Both authors were significantly involved in all steps of the writing process, including the conception, design, drafting and critical revision of the manuscript, as well as final approval for its submission.

PII: S0002-9343(09)00951-6

doi:10.1016/j.amjmed.2009.06.033

The American Journal of Medicine
Volume 123, Issue 3 , Pages 198-204, March 2010

Article Tools

* Image Usage & Resolution